Illumina, Inc. $ILMN Shares Sold by Fjarde AP Fonden Fourth Swedish National Pension Fund

Key Points

• The **Fjarde AP Fonden Fourth Swedish National Pension Fund** sold 5,700 shares of **Illumina, Inc.**, reducing its stake by **16.3%**, leaving it with **29,186 shares** valued at about **$2.316 million**.
• Research analysts have varied opinions on **Illumina**, resulting in a **consensus rating of "Hold" and an average target price of **$124.58**, with seven analysts rating it as a Buy and several downgrading their price targets recently.

Fjarde AP Fonden Fourth Swedish National Pension Fund reduced its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 16.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,186 shares of the life sciences company's stock after selling 5,700 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund's holdings in Illumina were worth $2,316,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Rakuten Securities Inc. grew its stake in shares of Illumina by 290.3% in the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock worth $29,000 after acquiring an additional 270 shares during the last quarter. Center for Financial Planning Inc. bought a new position in Illumina in the first quarter valued at about $33,000. Fourth Dimension Wealth LLC bought a new position in Illumina in the fourth quarter valued at about $40,000. PFS Partners LLC lifted its holdings in Illumina by 400.0% in the first quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock valued at $40,000 after acquiring an additional 400 shares during the period. Finally, Golden State Wealth Management LLC lifted its holdings in Illumina by 123.2% in the first quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company's stock valued at $42,000 after acquiring an additional 292 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Wall Street Zen downgraded Illumina from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Stephens set a $110.00 target price on Illumina and gave the stock an "overweight" rating in a research report on Monday, August 4th. Citigroup cut Illumina from a "hold" rating to a "strong sell" rating and cut their target price for the stock from $85.00 to $80.00 in a research report on Wednesday, July 9th. Evercore ISI increased their target price on Illumina from $116.00 to $128.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 8th. Finally, Piper Sandler cut their target price on Illumina from $190.00 to $185.00 and set an "overweight" rating for the company in a research report on Thursday, May 15th. Seven investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $124.58.

Illumina Trading Up 3.1%

Shares of Illumina stock traded up $3.1160 on Friday, reaching $102.4060. The company had a trading volume of 1,154,515 shares, compared to its average volume of 2,331,988. The firm has a market cap of $15.74 billion, a price-to-earnings ratio of 12.96, a P/E/G ratio of 2.27 and a beta of 1.37. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The firm's 50-day moving average price is $97.88 and its two-hundred day moving average price is $89.28. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm had revenue of $1.06 billion during the quarter, compared to analysts' expectations of $1.12 billion. During the same quarter in the previous year, the business earned $0.36 EPS. The company's quarterly revenue was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.